A 52-year-old woman with dilated cardiomyopathy and an ejection fraction of 28% is referred for arrhythmia evaluation. She has had two episodes of sustained monomorphic ventricular tachycardia in the past month. Regarding the electrophysiology and management of ventricular arrhythmias in cardiomyopathy, all of the following are true EXCEPT:

Explanation

## Ventricular Arrhythmias in Structural Heart Disease ### Correct Statements (Options 0, 1, 2) **Key Point:** Monomorphic VT in structural heart disease (e.g., cardiomyopathy, prior MI) arises from reentry around scar tissue. It has a fixed morphology and is more predictable than polymorphic VT, which often indicates acute ischemia or electrolyte derangement. **High-Yield:** ICD implantation is the gold standard for **secondary prevention** in patients with sustained VT/VF and hemodynamic compromise. LVEF ≤35% is the primary criterion for primary prevention; secondary prevention (prior VT/VF event) warrants ICD regardless of LVEF. **Clinical Pearl:** Catheter ablation has become a cornerstone of VT management. Mapping techniques (earliest activation, entrainment, pace-mapping) identify and ablate the reentrant circuit, reducing VT recurrence and arrhythmia burden in 50–80% of patients. ### Incorrect Statement (Option 3 — Correct Answer) **Warning:** Quinidine is **NOT superior** to beta-blockers or sotalol for VT suppression in dilated cardiomyopathy. In fact: 1. **Beta-blockers** (e.g., carvedilol, metoprolol) are first-line agents for VT suppression and reduce mortality in cardiomyopathy (CIBIS, COPERNICUS trials). 2. **Sotalol** (Class III antiarrhythmic with beta-blocking properties) is effective for VT suppression and is preferred over Class Ia agents like quinidine. 3. **Quinidine** (Class Ia) has a negative inotropic effect, increases mortality in cardiomyopathy, and is rarely used in modern practice due to proarrhythmic risk (especially in structural disease). **Mnemonic:** **SAFE VT Management in Cardiomyopathy** = **S**otalol/**A**miodarone, **F**irst-line **E**valuation with ICD; avoid **V**entricle-depressing **T**oxic agents like quinidine. ### Treatment Algorithm for Sustained VT in Cardiomyopathy ```mermaid flowchart TD A[Sustained VT + Cardiomyopathy]:::outcome --> B{Hemodynamically stable?}:::decision B -->|No| C[Immediate ICD + Amiodarone]:::action B -->|Yes| D[Risk stratify LVEF]:::decision D -->|LVEF ≤35%| E[ICD for secondary prevention]:::action D -->|LVEF >35%| F[Medical therapy trial]:::action F --> G[Beta-blocker or Sotalol]:::action G --> H{VT controlled?}:::decision H -->|Yes| I[Continue medical therapy]:::outcome H -->|No| J[Catheter ablation ± Amiodarone]:::action E --> K[Catheter ablation if recurrent]:::action ```